FY2025 EPS Estimate for Arcus Biosciences Lifted by Analyst

Key Points

• Cantor Fitzgerald raised its FY2025 EPS estimate for Arcus Biosciences from ($4.52) to ($3.69), indicating a more optimistic outlook for the company's earnings.
• Institutional investors hold 92.89% of Arcus Biosciences stock, with significant recent increases in holdings by firms such as Gilead Sciences Inc. and Vanguard Group Inc..
• Despite a quarterly loss, Arcus Biosciences reported revenue of $160 million, significantly surpassing analyst estimates of $32.86 million, and achieving a year-over-year revenue increase of 310.3%.

Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Investment analysts at Cantor Fitzgerald lifted their FY2025 earnings estimates for Arcus Biosciences in a research report issued to clients and investors on Thursday, August 7th. Cantor Fitzgerald analyst L. Watsek now expects that the company will post earnings per share of ($3.69) for the year, up from their prior estimate of ($4.52). The consensus estimate for Arcus Biosciences' current full-year earnings is ($3.15) per share. Cantor Fitzgerald also issued estimates for Arcus Biosciences' FY2026 earnings at ($4.22) EPS.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($1.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.14) by $0.03. The firm had revenue of $160.00 million for the quarter, compared to analysts' expectations of $32.86 million. Arcus Biosciences had a negative net margin of 109.56% and a negative return on equity of 55.96%. The company's revenue for the quarter was up 310.3% compared to the same quarter last year. During the same quarter last year, the business posted ($1.02) earnings per share.

RCUS has been the topic of several other research reports. The Goldman Sachs Group cut their price target on shares of Arcus Biosciences from $15.00 to $13.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. Wedbush reiterated an "outperform" rating and issued a $33.00 price target on shares of Arcus Biosciences in a report on Wednesday, May 7th. Barclays cut their price target on shares of Arcus Biosciences from $29.00 to $14.00 and set an "overweight" rating on the stock in a report on Wednesday, April 23rd. Wall Street Zen upgraded shares of Arcus Biosciences from a "strong sell" rating to a "hold" rating in a report on Saturday, August 9th. Finally, Morgan Stanley cut their price target on shares of Arcus Biosciences from $24.00 to $22.00 and set an "overweight" rating on the stock in a report on Friday, May 9th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $21.14.

Arcus Biosciences Trading Down 1.8%

NYSE RCUS traded down $0.18 on Monday, hitting $9.88. 251,334 shares of the stock were exchanged, compared to its average volume of 1,031,702. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.50 and a current ratio of 4.50. The stock has a fifty day moving average price of $9.15 and a two-hundred day moving average price of $9.39. The firm has a market capitalization of $1.05 billion, a P/E ratio of -3.11 and a beta of 0.89. Arcus Biosciences has a 52-week low of $6.50 and a 52-week high of $18.98.

Institutional Trading of Arcus Biosciences

A number of large investors have recently made changes to their positions in RCUS. CWM LLC raised its holdings in shares of Arcus Biosciences by 233.6% in the 2nd quarter. CWM LLC now owns 5,441 shares of the company's stock worth $44,000 after purchasing an additional 3,810 shares during the period. Lazard Asset Management LLC grew its stake in shares of Arcus Biosciences by 3,321.3% in the fourth quarter. Lazard Asset Management LLC now owns 6,261 shares of the company's stock valued at $93,000 after buying an additional 6,078 shares in the last quarter. Ameritas Investment Partners Inc. grew its stake in shares of Arcus Biosciences by 34.3% in the second quarter. Ameritas Investment Partners Inc. now owns 7,038 shares of the company's stock valued at $57,000 after buying an additional 1,796 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Arcus Biosciences by 440.3% in the second quarter. PNC Financial Services Group Inc. now owns 7,597 shares of the company's stock valued at $62,000 after buying an additional 6,191 shares in the last quarter. Finally, Strs Ohio acquired a new stake in shares of Arcus Biosciences in the first quarter valued at about $67,000. Institutional investors and hedge funds own 92.89% of the company's stock.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.